Literature DB >> 21631153

Residual undifferentiated cells during differentiation of induced pluripotent stem cells in vitro and in vivo.

Wei Fu1, Shu Jun Wang, Guang Dong Zhou, Wei Liu, Yilin Cao, Wen Jie Zhang.   

Abstract

Induced pluripotent stem (iPS) cells are a potential cell source for regenerative medicine. However, the tumorigenicity of iPS cells is a big concern for clinical application. In addition to the genetic manipulation of the reprogramming process and the greater risk of tumor formation, it is unclear whether iPS cells with normal development potential are still tumorigenic. Here, we investigated 3 mouse iPS cell lines, including one line that is able to generate full-term mice via tetraploid blastocyst complementation. We found that a small number of undifferentiated iPS cells could be steadily isolated and expanded after long-term differentiation of cells in vitro or in vivo. The residual undifferentiated iPS cells could be expanded and redifferentiated, and undifferentiated pluripotent stem cells could again be isolated after further rounds of differentiation, suggesting that residual undifferentiated iPS cells could not be eliminated by extended cell differentiation. The residual undifferentiated cells could form teratomas in vivo, indicating that they are a potential tumorigenic risk during transplantation. These findings prompt us to reconsider the strategies for solving the tumorigenic problem of iPS cells, not only focusing on improving the reprogramming process.

Entities:  

Mesh:

Year:  2011        PMID: 21631153     DOI: 10.1089/scd.2011.0131

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  22 in total

1.  FoxO3a contributes to the reprogramming process and the differentiation of induced pluripotent stem cells.

Authors:  Yongxiang Wang; Changhai Tian; Jialin C Zheng
Journal:  Stem Cells Dev       Date:  2013-08-09       Impact factor: 3.272

Review 2.  Stem cells technology: a powerful tool behind new brain treatments.

Authors:  Lucienne N Duru; Zhenzhen Quan; Talal Jamil Qazi; Hong Qing
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  Separation of in-vitro-derived megakaryocytes and platelets using spinning-membrane filtration.

Authors:  Alaina C Schlinker; Katherine Radwanski; Christopher Wegener; Kyungyoon Min; William M Miller
Journal:  Biotechnol Bioeng       Date:  2014-11-19       Impact factor: 4.530

4.  A Quick and Efficient Method for the Purification of Endoderm Cells Generated from Human Embryonic Stem Cells.

Authors:  Claudia Davenport; Ulf Diekmann; Ortwin Naujok
Journal:  J Vis Exp       Date:  2016-03-03       Impact factor: 1.355

5.  Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium.

Authors:  Lan Zhang; Yaohua Pan; Gangjian Qin; Lijuan Chen; Tapan K Chatterjee; Neal L Weintraub; Yaoliang Tang
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

Review 6.  Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy.

Authors:  Eirini P Papapetrou; Axel Schambach
Journal:  Mol Ther       Date:  2016-02-12       Impact factor: 11.454

Review 7.  Strategies for Oral Mucosal Repair by Engineering 3D Tissues with Pluripotent Stem Cells.

Authors:  Kyle J Hewitt; Yulia Shamis; Behzad Gerami-Naini; Jonathan A Garlick
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-12-01       Impact factor: 4.730

Review 8.  Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks.

Authors:  Fabrizio Rinaldi; Rita C R Perlingeiro
Journal:  Transl Res       Date:  2013-11-14       Impact factor: 7.012

Review 9.  Lessons from human teratomas to guide development of safe stem cell therapies.

Authors:  Justine J Cunningham; Thomas M Ulbright; Martin F Pera; Leendert H J Looijenga
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

10.  "Footprint-free" human induced pluripotent stem cell-derived astrocytes for in vivo cell-based therapy.

Authors:  Elisabetta Mormone; Sunita D'Sousa; Vera Alexeeva; Maria M Bederson; Isabelle M Germano
Journal:  Stem Cells Dev       Date:  2014-07-25       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.